Tilactase

Quick links to important sections

Tilactase

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tilactase

Defining Tilactase: Classification and Core Identity

Property Description
Active ingredient Tilactase (Beta-D-Galactosidase)
Form Tablet, Capsule, Solution (Infant Drops)
Pharmacological class Digestive Enzyme, Enzyme Replacement
Common use Supports digestion of dietary lactose
Origin Exogenous Enzyme (Microbial fermentation)

Tilactase is the established International Nonproprietary Name (INN) for a specialized pharmaceutical enzyme preparation, officially classified as an enzyme replacement within the hydrolase class of proteins. This medicine is designed to provide enzymatic support for individuals with hypolactasia, a common condition characterized by insufficient production of the natural lactase enzyme. Its general purpose is to supplement this deficiency, thereby assisting with the complete processing of the milk sugar lactose in the diet.


Active Ingredient, Origin, and Available Forms

The active component is Beta-D-Galactosidase (beta-Galactosidase), which performs the catalytic function. Tilactase is consistently a single-active ingredient product and is classified as an exogenous enzyme because it is derived from controlled microbial fermentation, often utilizing specific fungal or yeast strains. This targeted approach, widely available Over-The-Counter (OTC), is clinically recognized for effectively decreasing the gastrointestinal symptoms associated with lactose malabsorption. For oral administration, the medicine is supplied in various dosage forms, including capsules, chewable tablets, and solution (infant drops), offering flexible use for different patient groups.


Tilactase Function: General Purpose and Non-Systemic Action

Tilactase functions via the hydrolysis of lactose, a chemical reaction that splits the complex sugar lactose into two simpler, absorbable monosaccharides: glucose and galactose. This mechanism of effect is localized entirely within the contents of the Gastrointestinal (GI) tract and is classified as non-systemic. By ensuring the breakdown of lactose within the gut, the medicine provides functional support for digestion, preventing the undigested sugar from triggering uncomfortable symptoms in the colon.

What side effects are possible with Tilactase?

Possible Side Effects and Safety Information for Tilactase

The safety profile of Tilactase (beta-Galactosidase), as established by official government regulatory documents, is primarily defined by its non-systemic action, meaning the enzyme functions locally within the contents of the gastrointestinal (GI) tract. The incidence of adverse reactions outside of the GI system is considered low.


Documented Adverse Reactions and Frequency

Adverse reactions listed in regulatory documents are often categorized by Frequency Not Known, as the data cannot be reliably estimated from available clinical use, common for over-the-counter enzyme preparations. The System-Organ-Class (SOC) most frequently associated with reported events is Gastrointestinal disorders.

Classification Examples of Listed Adverse Effects
Gastrointestinal disorders Abdominal discomfort, flatulence, bloating, and temporary diarrhoea.
Immune System Disorders Hypersensitivity reactions (e.g., rash, pruritus) and, rarely, anaphylaxis.

Serious Adverse Reactions and Restrictions

While rare, the official safety labeling for Tilactase includes mention of serious adverse reactions related to systemic allergic responses to the protein, such as severe hypersensitivity reactions and Angioedema. The primary formal safety restriction is a Contraindication in individuals with a known hypersensitivity or allergy to the active substance, Tilactase, or any of the product’s excipients.

Safety is formally addressed for use in the Pediatric population, particularly for infants using the liquid drop formulations, which is consistent with its common use for managing symptomatic lactose malabsorption in this group. These classifications reflect how regulatory bodies organize and communicate the medicine’s safety and risk profile.

Overdose and Emergency Response

Overdose and when to seek help

This information is strictly based on documented statements from government regulatory authorities regarding the over-ingestion of Tilactase (Beta-D-Galactosidase), a non-systemic digestive enzyme.


Overdose Scope

Category Official Regulatory Statement/Finding
Documented overdose presentations Overdose presentations are primarily limited to an exaggeration of common gastrointestinal distress symptoms.
Physiological systems affected The system affected is the Gastrointestinal (GI) Tract. No specific systemic toxicity (e.g., cardiac, CNS, hepatic effects) is documented in association with over-ingestion.
Immediate help required Seek immediate medical attention in the event of suspected or known massive over-ingestion.

Overdose Management

Category Official Regulatory Statement/Finding
Severity classification Lack of documented systemic toxicity suggests a classification of low intrinsic acute toxicity in regulatory contexts.
Antidote availability No specific antidote is known or documented.
Supportive care Management consists solely of symptomatic and supportive treatment.

Official Summary

Regulatory authorities define the overdose profile of Tilactase based on its non-systemic action and low toxicity, limiting manifestations to localized gastrointestinal effects. Due to the absence of documented severe systemic outcomes, management is officially restricted to symptomatic and supportive treatment. However, regulators mandate that immediate medical help must be sought for any suspected over-ingestion to ensure appropriate clinical evaluation.

Therapeutic Uses of Tilactase

What Tilactase Treats: Main Uses and Benefits

Management of Gastrointestinal Symptoms from Lactose Intolerance

Tilactase is primarily used to address the cluster of digestive symptoms associated with hypolactasia, or lactose malabsorption. The underlying condition stems from a reduced ability to digest lactose. The medication is commonly used to help with disruptive manifestations like abdominal pain, cramping, flatulence, and bloating, which are symptoms related to physical discomfort. This therapeutic support is relevant for easing symptoms that interfere with daily comfort and is used in situations involving certain distressing symptoms linked to the diet.


Supportive Management for Diet and Comfort

The medication is generally used across all relevant patient groups—adults, children, and infants—for managing the symptoms associated with dietary lactose. It is applied in real-world scenarios when symptoms become more noticeable, and provides support that helps ease the overall symptom burden during periods of heightened symptoms. This supports individuals during difficult episodes by easing distress related to foods that may cause discomfort.

“Tilactase plays a role in managing symptoms of digestive discomfort tied to specific dietary intake.”


Quick Fact: Relief for Episodic Discomfort Tilactase is primarily relevant for conditions characterized by episodic or fluctuating symptom patterns that are directly triggered by the ingestion of lactose, and is used across domains where additional symptomatic support is needed.


Indications Summary: The primary therapeutic areas of use include managing the symptoms of lactose malabsorption, providing symptomatic relief for abdominal distress, and offering supportive management for the consumption of dairy products.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tilactase — official regulatory information

The regulatory eligibility profile for Tilactase (lactase enzyme) is based on guidelines for non-systemic, Over-The-Counter (OTC) products, focusing on hypersensitivity, age, and excipient-related warnings.

Category Official Regulatory Statement
Populations for whom use is allowed: Adults and older children (generally age four and up) are permitted to use the medicine under standard labeled conditions [Source 2.4, 2.1].
Populations for whom use is contraindicated: Individuals with a known allergy or severe hypersensitivity to the lactase enzyme or any excipients in the specific product formulation [Source 2.1].
Age-related eligibility rules: Children younger than 4 years old are restricted; regulatory labels advise that use in this population should occur only as recommended by a healthcare professional [Source 2.4, 2.3].
Condition-specific eligibility rules: Phenylketonuria (PKU): Eligibility is conditional; patients must check the specific product label due to the potential presence of aspartame or other phenylalanine sources [Source 2.4, 3.1].
Diabetes: Patients are officially directed to consult a doctor or healthcare provider before use [Source 2.1].
Renal/Hepatic Impairment: No explicit restrictions on eligibility are documented based on kidney or liver function [Source 1.2].
Pregnancy and lactation eligibility status: Conditional Use: Individuals who are pregnant or breastfeeding are consistently advised to "Ask a doctor" before using the product, as data on use in these populations is not fully established [Source 2.4, 2.1].

Connection to the overall eligibility profile: The official regulatory documentation defines eligibility through an absolute contraindication for allergy, a specific age restriction for unsupervised pediatric use, and conditional use requirements for metabolic conditions and reproductive status. This structure confirms that eligibility for use is broad but subject to specific safety checks tied to the product's formulation and the patient's age and allergy status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tilactase, an exogenous digestive enzyme, is characterized by a non-systemic mechanism of action. Because the active ingredient is not absorbed into the bloodstream, regulatory documents consistently report a definitive absence of systemic drug-drug interactions for the enzyme itself. This profile defines the interaction structure for the product across official regulatory labeling.

Interaction Type Official Regulatory Statement
Drug-Drug Interactions None documented. Tilactase does not affect the clearance or plasma concentration (Cmax or AUC) of co-administered systemic medicines.
Metabolic/CYP Interactions None. The enzyme is not involved as a substrate, inhibitor, or inducer of Cytochrome P450 (CYP) enzymes.
Contraindicated Combinations No medicines are explicitly listed as contraindicated for co-administration with Tilactase due to interaction risk.

This absence of systemic interaction eliminates the need for mandatory administration timing separation between Tilactase and other prescribed medicinal products.

Population-Specific Restrictions

The only official restriction tied to the product is based on excipient content in certain oral formulations. Products formulated as chewable tablets or solutions may contain aspartame, which is a source of phenylalanine. Regulatory documentation mandates a specific restriction for its use in patients diagnosed with phenylketonuria (PKU). This restriction is related to the product's inactive ingredients, not to an interaction mechanism involving the active enzyme.

Mechanism of Action

Tilactase is an exogenous boldsymbolbeta-galactosidase enzyme introduced into the gastrointestinal tract. Its biological target is the disaccharide lactose. Tilactase acts via catalytic hydrolysis, cleaving the beta-glycosidic bond of lactose into its constituent monosaccharides, boldsymbolD-glucose and boldsymbolD-galactose.

This enzymatic transformation occurs efficiently at the acidic mathrmpH environment of the upper gastrointestinal tract, specifically the small intestine, simulating the activity of endogenous lactase. The downstream cascade involves increasing the concentration of simple, absorbable sugars available for enterocyte uptake. This modification of the digestive pathway prevents unhydrolyzed lactose from progressing to the colon.

The system-level physiological consequence of preventing unabsorbed lactose from entering the lower GI tract is the modulation of osmotic pressure. The absence of the undigested disaccharide reduces the osmotic gradient in the colon, limiting the influx of water and preventing subsequent molecular consequences of bacterial fermentation.

Dosage and Administration Information

Instruction Map: How to use Tilactase — Official Administration Guidelines

Administration Scope

Instruction Detail
Route of administration: Oral administration only.
Dosing schedule (as written in regulatory sources): A non-fixed dose of 3,000 to 9,000 Units (FCC ALU) is taken per serving of dairy food. The amount is adjusted based on individual sensitivity and estimated lactose content.
Timing in relation to meals (if applicable): Must be taken with the first bite or sip of any lactose-containing food.
Preparation requirements (if applicable): Infant Drops must be added to warm (body temperature) milk or formula and must not be mixed with boiling liquids. Chewable tablets must be fully chewed.
Age-group administration rules: Children ge 4 years generally follow the adult unit range. Infants require specific liquid dosing and preparation procedures.
Missed-dose rules: If a dose is missed, it should be taken as soon as possible during the meal; double doses are not permitted.
Special procedural conditions: An additional dose may be taken if consumption continues beyond approximately 30 to 45 minutes. Pre-mixed infant formula must be used within 12 hours.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral
Frequency pattern: As-needed (episodic), tied directly to lactose ingestion.
Regulatory basis: Based on consensus from official labeling and pharmaceutical standards.
Use-context constraints (as defined in official documents): Concurrent timing with food intake is mandatory; temperature sensitivity restricts mixing with hot liquids.

Resulting Procedural Structure

Official step sequence:

  • The dosage, measured in FCC ALU, is determined relative to the anticipated lactose load of the meal.
  • The enzyme must be administered concurrently with the first intake of the dairy product.
  • If using liquid drops, ensure the liquid is only warm (body temperature), as the enzyme is heat-sensitive.
  • The dose may be repeated if the consumption period of the dairy product is prolonged.

Connection to the overall use protocol (2–4 sentences): Official regulatory instructions define a strict non-systemic, episodic use protocol that ties administration to the timing of dietary lactose intake. This protocol mandates precise dose-timing synchronization with the start of the meal and requires adherence to specific form- and age-dependent preparation steps to ensure effectiveness in the digestive tract. The guidelines structure the correct use by detailing the circumstances, route, and frequency of administration.

Recent Clinical Evidence

Tilactase: Recent Clinical Evidence

Mechanism and Primary Action

Research has explored the use of Tilactase, the enzyme beta-galactosidase, as a dietary supplement. Studies indicate that Tilactase helps hydrolyze lactose (a disaccharide) into its monosaccharide components, glucose and galactose, mimicking the function of the naturally occurring human enzyme lactase in the small intestine. This action addresses the deficiency associated with lactose intolerance. Research is available investigating the enzyme's stability and effectiveness under the acidic conditions of the human stomach.


Clinical Efficacy and Outcomes

Studies comparing Tilactase supplementation to placebo have been conducted to investigate differences in patient-reported symptom severity following lactose ingestion. Research focuses on quantifying changes in gastrointestinal symptoms such as bloating, cramping, and flatulence in individuals diagnosed with lactose intolerance. The primary goal of this research is to evaluate if Tilactase use is associated with improved digestive comfort.

Dosage and Formulation Research

Clinical research has explored the relationship between the enzyme units (measured in FCC units) administered and the resulting degree of lactose hydrolysis, especially when consumed alongside food containing varying amounts of lactose. Investigations compare different formulations (e.g., chewable tablets vs. capsules) to examine potential differences in enzyme delivery and effect onset.


Safety and Tolerability Research

Tilactase is generally considered a well-tolerated dietary enzyme supplement. Safety studies investigate the frequency of adverse effects across different age groups and dosages. These studies primarily report mild, infrequent gastrointestinal disturbances, which are typically comparable to placebo groups. No severe safety concerns have been widely reported in available clinical literature focused on its use for lactose digestion.

Key Studies & References

  1. Advances in $beta$-Galactosidase Research: A Systematic Review from Molecular Mechanisms to Enzyme Delivery Systems
  2. Lactase for infantile colic: A systematic review of randomized clinical trials
  3. Comparison of the Effectiveness of Oral Lactase Enzyme and Lactose Free Formula in the Management of Secondary Lactose Intolerance in Persistent and Severe Persistent Diarrhea (NCT06827405)

Frequently Asked Questions (FAQ)

Common questions about Tilactase (FAQ)

Q: Is Tilactase considered a 'drug' or a 'dietary supplement' in official sources?

A: Official classification can vary depending on the country and the specific product formulation. In some regions, Tilactase (Lactase Enzyme) is categorized as an Over-the-Counter (OTC) medicine or a Natural Health Product (NHP)/dietary enzyme supplement. These classifications reflect the regulatory process used to approve the product for public sale.

Q: How quickly does Tilactase start working after taking it?

A: Official administration instructions require the product to be taken with the first bite or sip of lactose-containing food. This precise timing is emphasized because the enzyme needs to be present in the digestive tract to efficiently support the breakdown of lactose as the food is ingested.

Q: How long do the effects of one dose of Tilactase typically last?

A: Regulatory documents suggest a timeframe for enzyme activity by noting that the dose may be repeated if the period of lactose consumption continues beyond approximately 30 to 45 minutes. This timeframe suggests the period during which functional support for lactose digestion may be provided by a single dose.

Q: Does alcohol consumption affect how Tilactase works in the body?

A: Official labeling for this digestive enzyme does not list alcohol consumption as an interaction or avoidance required for the proper functioning of the product. Tilactase acts locally in the digestive tract and is not absorbed into the bloodstream like systemic medicines.

Q: Are there any known issues with taking Tilactase alongside probiotic supplements?

A: Regulatory documents report an absence of systemic drug-drug interactions because the enzyme is non-systemic; it is not absorbed into the bloodstream. This means it does not typically affect how other medicines or supplements, like probiotics, work throughout the body.

Q: Is Tilactase suitable for someone who is vegetarian or vegan?

A: The active enzyme is derived from microbial fermentation, which is a non-animal source. However, official regulatory documentation often requires consumers to check the specific product label, as the source of non-active ingredients, or excipients (e.g., capsule materials), may vary by formulation.

Q: Does Tilactase contain gluten, and is it safe for people with celiac disease?

A: Regulatory standards generally state that the vast majority of oral enzyme supplements contain no gluten or virtually undetectable levels. Specific gluten warnings are not standard unless excipients derived from gluten-containing grains are used. It is important that individuals confirm specific allergen information on the product label.

Q: What happens if I take Tilactase but then don't eat any dairy?

A: Regulatory texts imply no concern. The enzyme acts locally in the digestive tract only when lactose is present. Due to its non-systemic action, the product is simply broken down by the body without an active target, and an overdose is unlikely to cause serious symptoms.

Q: Why do some people say Tilactase doesn't work for them?

A: Official guidance indicates that effectiveness is dependent on strict adherence to the administration protocol. This includes concurrent timing with the first intake of dairy and temperature avoidance (e.g., mixing with boiling liquids, which can destroy the enzyme). Clinical research has also noted variable outcomes in patient response to enzyme supplementation.

Q: Do the official documents mention long-term use of Tilactase?

A: Official regulatory monographs for lactase supplements advise that a health care practitioner be consulted for prolonged use of the product. This recommendation supports the appropriate management of chronic symptoms.

Q: Is it okay to crush or chew the Tilactase tablets or capsules?

A: Official administration guidelines mandate that chewable tablets must be fully chewed to ensure effectiveness. Any modification to other forms, such as opening or crushing capsules, is not standardly addressed in regulatory instructions for use.

Q: Can I use Tilactase if I have irritable bowel syndrome (IBS) or Crohn's disease?

A: Regulatory monographs indicate that consultation with a health care practitioner may be warranted before use if a consumer has a pre-existing gastrointestinal disturbance or chronic condition. This is a general safety precaution applied to over-the-counter products that affect the digestive system.

Q: Is it necessary to have a formal diagnosis of lactose intolerance to use Tilactase?

A: No. Official documentation describes the product as being widely available Over-The-Counter (OTC). OTC availability is typically intended for self-selection by consumers experiencing common, non-severe symptoms without requiring a mandatory formal diagnosis.

Q: Does the strength (e.g., International Units or IU) on the Tilactase label matter?

A: Yes, the strength matters for dosing. Official guidelines define the dose by the product's strength, which is measured in FCC ALU (Food Chemicals Codex Acid Lactase Units). The dose is adjusted based on the individual's level of sensitivity and the estimated lactose content of the meal being consumed.

Q: What are the potential signs of an overdosage of Tilactase?

A: Official patient information states that an overdose of the lactase enzyme is unlikely to cause serious symptoms. This is because the enzyme works locally in the digestive tract and is not absorbed into the bloodstream.

Q: Do older adults need to adjust their Tilactase usage compared to younger people?

A: Regulatory labeling for this non-systemic enzyme does not document explicit restrictions or dosage adjustments specifically for older adults compared to other adult populations. Standard dosing guidance applies across the adult age range.

Q: Can using Tilactase cause other digestive issues like constipation?

A: Documented adverse reactions are generally limited to gastrointestinal issues such as abdominal discomfort, flatulence, bloating, and temporary diarrhoea. Constipation is not typically listed among the commonly reported side effects.

Q: Is it normal for symptoms to slightly remain even when taking Tilactase?

A: Clinical research has examined whether the enzyme is associated with improved digestive comfort and a reduction in the severity of symptoms. However, clinical studies have noted variable outcomes in different people, implying that the complete elimination of all symptoms is not guaranteed.

Q: Is there an expiration date on Tilactase products, and does it lose potency over time?

A: Official labeling states that expired products should be discarded. Warnings are also provided that extreme darkening or turbidity from heat or light indicates a loss of stability and potency, and the product should not be used in that state.

How should Tilactase be stored and disposed of?

Storage and Disposal Requirements for Tilactase

Official labeling defines strict environmental and container requirements to ensure the stability and safe handling of tilactase (lactase enzyme).


Required Storage Conditions

Tilactase must be stored at controlled room temperature, typically 20^circ to 25 C (68^circ to 77 F). The product must be protected from light and stored in a tight, light-resistant container that is kept tightly closed. Storage temperatures above 30 C and freezing must be avoided. If the product develops extreme darkening or turbidity from heat or light exposure, it indicates a loss of stability and should not be used.

Safety and Disposal

For safety, the medicine must be kept out of reach of children, and the container is required to have a child-resistant closure. Any unused or expired product must be discarded and disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tilactase found in:

A-Z Index: